Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.

Journal of Clinical Oncology, Vol 15, 1131-1137, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte

C Haioun, E Lepage, C Gisselbrecht, Y Bastion, B Coiffier, P Brice, A Bosly, B Dupriez, C Nouvel, H Tilly, P Lederlin, P Biron, J Briere, P Gaulard and F Reyes
Hopital Henri Mondor, Creteil, France. corinne.haioun@hmn.ap-hop- paris.fr

PURPOSE: To update the randomized study that compared consolidative sequential treatment (ifosfamide, etoposide, asporaginase, and cytarabine) versus the high-dose regimen of cyclophosphamide, carmustine, and etoposide (CBV) followed by autotransplantation in patients with aggressive non-Hodgkin's lymphoma in first complete remission and to focus on high-intermediate and high-risk patients identified by the international prognostic index. PATIENTS AND METHODS: Nine hundred sixteen patients received induction treatment on the LNH84 protocol with open randomization for the anthracycline. In a subsequent randomization, 541 patients in complete remission were assigned to receive consolidation by either sequential chemotherapy (n = 273) or autotransplant (n = 268). Among the higher risk population (two or three risk factors), 236 patients in complete remission were assessable for the consolidation phase, with 111 in the sequential chemotherapy arm and 125 in the autotransplant arm. RESULTS: Among 541 randomized patients, disease-free survival and survival did not differ significantly between the two consolidative treatment arms. In the higher risk population, CBV was superior to sequential chemotherapy, with 5-year disease-free survival rates of 59% (95% confidence interval, 49% to 69%) and 39% (95% confidence interval, 28% to 50%), respectively (P = .01, relative risk = 1.19). The 5-year survival rate was superior in the CBV group at 65% (95% confidence interval, 56% to 74%) compared with 52% in the sequential chemotherapy group (95% confidence interval, 42% to 62%) (P = .06, relative risk = 1.49). CONCLUSION: This study shows a superior disease-free survival for higher risk patients in complete remission. Dose-intensive consolidation therapy should be considered for patients at higher risk who achieve complete remission after induction treatment.


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, et al.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann. Onc., November 1, 2008; 19(11): 1935 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc., March 1, 2008; 19(3): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Blood, October 1, 2007; 110(7): 2316 - 2323.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Betticher, G Martinelli, J. Radford, M Kaufmann, M. Dyer, U Kaiser, W. Aulitzky, J Beck, A von Rohr, T Kovascovics, et al.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
Ann. Onc., October 1, 2006; 17(10): 1546 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 IEICE Trans ElectronHome page
K. IIYAMA, M. YASUDA, and S. TAKAMIYA
Extended-Range High-Resolution FMCW Reflectometry by Means of Electronically Frequency-Multiplied Sampling Signal Generated from Auxiliary Interferometer
IEICE Trans C: Electronics, June 1, 2006; E89-C(6): 823 - 829.
[Abstract] [PDF]

Home page
 BloodHome page
B. Glass, M. Kloess, M. Bentz, G. Schlimok, W. E. Berdel, A. Feller, L. Trumper, M. Loeffler, M. Pfreundschuh, N. Schmitz, et al.
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
Blood, April 15, 2006; 107(8): 3058 - 3064.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Olivieri, G. Santini, C. Patti, T. Chisesi, C. De Souza, A. Rubagotti, S. Aversa, A. Billio, A. Porcellini, M. Candela, et al.
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG
Ann. Onc., December 1, 2005; 16(12): 1941 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. A. Gregory and L. Trumper
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Ann. Onc., September 1, 2005; 16(9): 1413 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. W. van Imhoff, B. van der Holt, M. A. MacKenzie, M. B. van't Veer, P. W. Wijermans, G. J. Ossenkoppele, H. C. Schouten, P. Sonneveld, M. M.C. Steijaert, P. M. Kluin, et al.
Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40
J. Clin. Oncol., June 1, 2005; 23(16): 3793 - 3801.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., December 1, 2004; 15(12): 1790 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Bertz, R. Zeiser, W. Lange, S. Fetscher, C. F. Waller, and J. Finke
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index
Ann. Onc., September 1, 2004; 15(9): 1419 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., July 15, 2004; 22(14): 2826 - 2834.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, et al.
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Blood, April 1, 2004; 103(7): 2474 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. Milpied, E. Deconinck, F. Gaillard, V. Delwail, C. Foussard, C. Berthou, R. Gressin, V. Lucas, P. Colombat, J.-L. Harousseau, et al.
Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support
N. Engl. J. Med., March 25, 2004; 350(13): 1287 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Coiffier
Increasing Chemotherapy Intensity in Aggressive Lymphomas: A Renewal?
J. Clin. Oncol., July 1, 2003; 21(13): 2457 - 2459.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. D. Caballero, J. A. Perez-Simon, A. Iriondo, J. J. Lahuerta, J. Sierra, J. Marin, M. Gandarillas, R. Arranz, J. Zuazu, V. Rubio, et al.
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group
Ann. Onc., January 1, 2003; 14(1): 140 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Balzarotti, M. Spina, B. Sarina, M. Magagnoli, L. Castagna, I. Milan, C. Ripa, F. Latteri, D. Bernardi, A. Bertuzzi, et al.
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide
Ann. Onc., September 1, 2002; 13(9): 1341 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. A. Sparano, E. Weller, T. Nazeer, T. Habermann, A. E. Traynor, J. Manalo, and P. Cassileth
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)
Blood, August 13, 2002; 100(5): 1634 - 1640.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gisselbrecht, E. Lepage, T. Molina, B. Quesnel, G. Fillet, P. Lederlin, B. Coiffier, H. Tilly, J. Gabarre, F. Guilmin, et al.
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma
J. Clin. Oncol., May 15, 2002; 20(10): 2472 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al.
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
Ann. Onc., March 1, 2002; 13(3): 450 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Filipits, U. Jaeger, G. Pohl, T. Stranzl, I. Simonitsch, A. Kaider, C. Skrabs, and R. Pirker
Cyclin D3 Is a Predictive and Prognostic Factor in Diffuse Large B-cell Lymphoma
Clin. Cancer Res., March 1, 2002; 8(3): 729 - 733.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. T. Kouroukis, G. P. Browman, R. Esmail, and R. M. Meyer
Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma: A Systematic Review
Ann Intern Med, January 15, 2002; 136(2): 144 - 152.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg
Stem Cell Transplantation: Supportive Care and Long-Term Complications
Hematology, January 1, 2002; 2002(1): 422 - 444.
[Abstract] [Full Text]

Home page
 The OncologistHome page
S. A. Mink and J. O. Armitage
High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma
Oncologist, June 1, 2001; 6(3): 247 - 256.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. van Besien, M. Kelta, and P. Bahaguna
Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management
J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou, D. Bron, K. J. Roozendaal, E. M. Noordijk, H. Musson, I. Teodorovic, B. Maes, A. Carbone, et al.
Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study
J Natl Cancer Inst, January 3, 2001; 93(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Mohr, F. Dalmis, E. Hilgenfeld, E. Oelmann, M. Zühlsdorf, K. Kratz-Albers, A. Nolte, C. Schmitmann, D. Önaldi-Mohr, U. Cassens, et al.
Simultaneous Immunomagnetic CD34+ Cell Selection and B-Cell Depletion in Peripheral Blood Progenitor Cell Samples of Patients Suffering from B-Cell Non-Hodgkin's Lymphoma
Clin. Cancer Res., January 1, 2001; 7(1): 51 - 57.
[Abstract] [Full Text]

Home page
 The OncologistHome page
S. Rodenhuis
The Status of High-Dose Chemotherapy in Breast Cancer
Oncologist, October 1, 2000; 5(5): 369 - 375.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker
Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas
Clin. Cancer Res., September 1, 2000; 6(9): 3417 - 3423.
[Abstract] [Full Text]

Home page
 BloodHome page
C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, et al.
Prognostic significance of survivin expression in diffuse large B-cell lymphomas
Blood, September 1, 2000; 96(5): 1921 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Haioun, E. Lepage, C. Gisselbrecht, G. Salles, B. Coiffier, P. Brice, A. Bosly, P. Morel, C. Nouvel, H. Tilly, et al.
Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Analysis of the Prospective LNH87-2 Protocol--A Groupe d'Etude des Lymphomes de l'Adulte Study
J. Clin. Oncol., August 16, 2000; 18(16): 3025 - 3030.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. D. Baynes, C. Hamm, R. Dansey, J. Klein, L. Cassells, C. Karanes, E. Abella, and W. P. Peters
Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting
Clin. Chem., August 1, 2000; 46(8): 1239 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mounier, C. Haioun, B. F. Cole, C. Gisselbrecht, C. Sebban, P. Morel, G. Marit, R. Bouabdallah, C. Ravoet, G. Salles, et al.
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission
Blood, June 15, 2000; 95(12): 3687 - 3692.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Tilly, N. Mounier, P. Lederlin, J. Briere, B. Dupriez, C. Sebban, A. Bosly, P. Biron, C. Nouvel, R. Herbrecht, et al.
Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study
J. Clin. Oncol., March 13, 2000; 18(6): 1309 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Aristei and A. Tabilio
Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases
Oncologist, October 1, 1999; 4(5): 386 - 397.
[Abstract] [Full Text]

Home page
 The OncologistHome page
M. L. Grossbard
Hematologic Malignancies
Oncologist, August 1, 1999; 4(4): 287 - 292.
[Full Text]

Home page
 Clin. Cancer Res.Home page
M. Mohr, E. Hilgenfeld, T. Fietz, B. Hoppe, M. Koenigsmann, M. Hoffmann, W. U. Knauf, U. Cassens, W. Sibrowski, J. Kienast, et al.
Efficacy and Safety of Simultaneous Immunomagnetic CD34+ Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy
Clin. Cancer Res., May 1, 1999; 5(5): 1035 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M.A. Shipp, M.D. Abeloff, K.H. Antman, G. Carroll, A. Hagenbeek, M. Loeffler, E. Montserrat, J.A. Radford, G. Salles, N. Schmitz, et al.
International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury
J. Clin. Oncol., January 1, 1999; 17(1): 423 - 423.
[Full Text] [PDF]

Home page
 BloodHome page
J.-Y. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron, C. Guglielmi, A. Hagenbeek, R. Somers, F. Chauvin, and T. Philip
The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: Analysis of the PARMA Trial
Blood, November 15, 1998; 92(10): 3562 - 3568.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.H. Weaver, W. West, L. Schwartzberg, R. Birch, and C.D. Buckner
The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers
Oncologist, October 1, 1998; 3(5): 346 - 353.
[Abstract] [Full Text]

Home page
 BloodHome page
C. Gisselbrecht, P. Gaulard, E. Lepage, B. Coiffier, J. Briere, C. Haioun, D. Cazals-Hatem, A. Bosly, L. Xerri, H. Tilly, et al.
Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas
Blood, July 1, 1998; 92(1): 76 - 82.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist, June 1, 1998; 3(3): 189 - 197.
[Abstract] [Full Text]

Home page
 BloodHome page
N. Ketterer, G. Salles, M. Raba, D. Espinouse, A. Sonet, P. Tremisi, C. Dumontet, I. Moullet, A. Eljaafari-Corbin, E.-M. Neidhardt-Berard, et al.
High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation
Blood, May 1, 1998; 91(9): 3148 - 3155.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. J. Deeg and G. Socie
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
Blood, March 15, 1998; 91(6): 1833 - 1844.
[Full Text] [PDF]

Home page
 BloodHome page
L. H. Sehn, J. H. Antin, L. N. Shulman, P. Mauch, A. Elias, M. E. Kadin, and C. Wheeler
Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation
Blood, January 15, 1998; 91(2): 717 - 723.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Nademanee, A. Molina, M. R. O'Donnell, A. Dagis, D. S. Snyder, P. Parker, A. Stein, E. Smith, I. Planas, A. Kashyap, et al.
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group
Blood, November 15, 1997; 90(10): 3844 - 3852.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online